Current Report Filing (8-k)
15 Giugno 2023 - 10:58PM
Edgar (US Regulatory)
0001412486
false
0001412486
2023-06-15
2023-06-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 15, 2023
Cocrystal
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-38418 |
|
35-2528215 |
(State
or other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
19805
N. Creek Parkway
Bothell,
WA |
|
98011 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (786) 459-1831
(Former
name or former address, if changed since last report.):
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
COCP |
|
The
Nasdaq Stock Market LLC
(The Nasdaq Capital Market) |
Item
8.01 Other Events.
In
connection with the At-The-Market Offering Agreement entered into between Cocrystral Pharma, Inc. (the “Company”) and H.C.
Wainwright & Co., LLC (“Wainwright”) on July 1, 2020 (the “Agreement”), on June 15, 2023 the Company filed
a prospectus supplement under its replacement shelf registration statement on Form S-3 (File No. 333-271883) (the “Registration
Statement”) for the offering of up to $7,250,000 shares of common stock (the “Shares”) pursuant to the Agreement. The
Agreement, including a description of the material terms thereof was previously disclosed in the Company’s Current Report on Form
8-K filed on July 2, 2020, and a copy of the Agreement was filed as Exhibit 1.1 thereto. This Current Report on Form 8-K is being filed
to incorporate by reference into the Registration Statement the opinion and consent of the Company’s counsel with respect to the
validity of the Shares being offered and sold in the offering, which are filed as Exhibits 5.1 and 23.1, respectively, to this Current
Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Cocrystal
Pharma, Inc. |
| |
|
|
| Date:
June 15, 2023 |
By: |
/s/
James Martin |
| |
Name: |
James
Martin |
| |
Title: |
Co-Chief Executive Officer and Chief Financial Officer |
Grafico Azioni Cocrystal Pharma (NASDAQ:COCP)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Cocrystal Pharma (NASDAQ:COCP)
Storico
Da Gen 2024 a Gen 2025
